LJ International Inc. JADE 深 滬
等待開盤 07-22 09:30:00 美东时间
55.0314
+0.293
+0.54%
華盛通- 最 高55.16
- 今 開55.16
- 成交量 642股
- 最 低 55.0314
- 昨 收 54.7383
- 總市值 1650.94万
- 52周最高 55.16
- 市盈率 靜 --
- 換手率 0.21%
- 52周最低 42.18
- 委 比 0.00%
- 總股本 30.00万
- 歷史最高 55.16
- 量 比 0
- 振 幅 0.23%
- 歷史最低 42.18
- 每 手 1
- 風險率 2.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jade Biosciences to Participate in Two Upcoming Investor Conferences
Jade Biosciences announced its participation in two upcoming investor conferences. CEO Tom Frohlich and CSO Andrew King will discuss the company's pipeline, including JADE101 for immunoglobulin A nephropathy, at the H.C. Wainwright Kidney Virtual Conference on July 14 and the Stifel Biotech Summer Summit on August 13. Both events will include fireside chats and one-on-one investor meetings. Jade is focused on developing best-in-class therapies fo...
07-08 11:00
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
Jade Biosciences, Inc., a biotech company focused on autoimmune diseases, has appointed Brad Dahms as its Chief Financial Officer. Dahms, with a strong track record in biotech finance and strategic leadership, joins Jade to support its growth, including advancing its lead candidate JADE101 for IgA nephropathy into clinical trials in 2025. His prior experience includes roles at IDRx, Theseus Pharmaceuticals, and Selecta Biosciences, where he led f...
07-01 11:00
Jade Road Investments Delays 2024 Annual Report
Jade Road Investments ( ($GB:JADE) ) has provided an announcement. Jade Road In...
07-01 03:46
Jade Biosciences Presents Detailed Preclinical Characterization Of JADE101 In Development For IgAN, Chronic Autoimmune Kidney Disease; First-In-Human Trial Expected To Begin H2 2025
Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppressionIn non-human primates, JADE101 showed a differentiated
06-09 19:03
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress
Jade Biosciences, Inc. announced that new preclinical data on JADE101, its anti-APRIL monoclonal antibody for treating IgA nephropathy, will be presented at the 62nd ERA Congress in Vienna on June 6, 2025. The company will host a conference call and webcast on June 9, 2025, to discuss the data. JADE101 targets APRIL to reduce pathogenic IgA, decrease proteinuria, and preserve kidney function. A replay of the webcast will be available on the compa...
06-02 11:00
Jade Road Investments Awaits Closure of £1 Million Subscription Agreement
Jade Road Investments ( ($GB:JADE) ) just unveiled an announcement. Jade Road I...
05-27 23:07
Jade Road Investments Awaits Fund Receipt for Subscription Agreement
An announcement from Jade Road Investments ( ($GB:JADE) ) is now available. Jad...
05-06 22:02
Jade Leader Corp Announces New Jade Discoveries
Jade Leader Corp (TSE:JADE) has released an update. Jade Leader Corp has succes...
2024-12-20 02:33
Aerovate Therapeutics And Privately-held Jade Biosciences Have Entered Into A Definitive Merger Agreement For An All-stock Transaction, The Resulting Entity Will Focus On Advancing Jade's Portfolio Of Biologics, Including JADE-001 For IgA Nephropathy
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseasesJade Biosciences, the fourth company founded
2024-10-31 19:23
Jade Road’s H1 2024: Reduced Income and Net Loss
Jade Road Investments Limited (GB:JADE) has released an update. Jade Road Inves...
2024-09-30 14:58
